Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Non-Small-Cell Lung × Vinorelbine × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Rhabdomyosarcoma, Embryonal 1 Rhabdomyosarcoma, Alveolar 1 Rhabdomyosarcoma 1 Recurrence 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Hodgkin Disease 1 HR+HER2- Breast Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

pembrolizumab 59 Carboplatin 57 Pemetrexed 47 Cisplatin 36 Paclitaxel 28 Specimen Handling 26 Nivolumab 24 durvalumab 22 Magnetic Resonance Spectroscopy 20 osimertinib 19 Docetaxel 19 Gemcitabine 13 atezolizumab 12 amivantamab 11 Radiotherapy 11 Ipilimumab 11 cemiplimab 10 Cetuximab 10 Drug Therapy 9 130-nm albumin-bound paclitaxel 9 Radiosurgery 8 lazertinib 7 Taxes 7 Bevacizumab 7 Radiation 6 Observation 6 sotorasib 5 alectinib 5 adagrasib 5 Ramucirumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07001618 2026-04-03

IMMUNOLIFE2

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡